Director Janney Daniel sold 11.8K shares at $275.59 avg, reducing stake 13.9% to 73.3K; stock now 9.6% below 52-week high
Director Janney Daniel executed two separate sales on 2026-02-27, selling 9,430 shares at $275.45 and 2,373 shares at $276.17, for a combined $3,252,824.34 and a blended average price of $275.59. This represents a 13.9% reduction of his post-transaction holdings to 73.3K shares. The timing is noteworthy: the sales occurred near the 52-week high (stock currently $263.80, which is 9.6% below the $291.93 52-week high), though today's price is also down 5.5% over the past 30 days despite a +21.3% gain over 90 days. Krystal Biotech shows strong fundamentals with latest quarterly revenue of $97,800,000.00, net income of $79,365,000.00, and annual revenue growth of +33.9%, paired with a P/E of 24.52, suggesting the company is valued at a meaningful premium. The director's prior same-ticker activity (5 trades in recent days: 2026-02-26, 2026-02-25, and 2026-02-24) shows a pattern of recent dispositions, though outcomes are not yet measurable and the cross-ticker track record shows 20 prior sells without measurable 90-day timing data at this ticker.